Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing
Evaxion Biotech (NASDAQ: EVAX) has received a delisting determination from Nasdaq due to failure to maintain stockholders' equity of at least $2.5 million. The company has appealed the decision and requested a hearing, seeking another 180-day extension to comply with Nasdaq's equity requirements. The appeal will suspend any trading suspension until the hearing process concludes. This follows a previous deficiency letter received on May 7, 2024, after which Evaxion was granted a 180-day extension that expired on November 4, 2024. The company plans to increase stockholder's equity through business development income and capital markets activities, though compliance cannot be guaranteed.
Evaxion Biotech (NASDAQ: EVAX) ha ricevuto una determinazione di esclusione da parte di Nasdaq a causa del mancato mantenimento di un patrimonio azionario di almeno 2,5 milioni di dollari. L'azienda ha presentato ricorso contro la decisione e ha richiesto un'udienza, cercando un'estensione di altri 180 giorni per conformarsi ai requisiti patrimoniali di Nasdaq. Il ricorso sospenderà qualsiasi sospensione della negoziazione fino al termine del processo di udienza. Questo segue una lettera di carenza ricevuta il 7 maggio 2024, dopo la quale a Evaxion è stata concessa un'estensione di 180 giorni che è scaduta il 4 novembre 2024. L'azienda prevede di aumentare il patrimonio degli azionisti attraverso redditi da sviluppo aziendale e attività nei mercati dei capitali, anche se la conformità non può essere garantita.
Evaxion Biotech (NASDAQ: EVAX) ha recibido una determinación de exclusión de Nasdaq debido a la falta de mantener un patrimonio neto de al menos 2,5 millones de dólares. La compañía ha apelado la decisión y ha solicitado una audiencia, buscando una prórroga de 180 días adicionales para cumplir con los requisitos de patrimonio de Nasdaq. La apelación suspenderá cualquier suspensión de negociación hasta que se concluya el proceso de audiencia. Esto sigue a una carta de deficiencia recibida el 7 de mayo de 2024, tras la cual Evaxion recibió una prórroga de 180 días que expiró el 4 de noviembre de 2024. La compañía planea aumentar el patrimonio de los accionistas a través de ingresos por desarrollo empresarial y actividades en los mercados de capital, aunque no se puede garantizar el cumplimiento.
Evaxion Biotech (NASDAQ: EVAX)는 최소 250만 달러의 주주 자본을 유지하지 못해 나스닥으로부터 상장 폐지 결정을 받았습니다. 회사는 결정에 대해 항소하고 청문회를 요청했으며 나스닥의 자본 요구 사항을 준수하기 위해 180일 추가 연장을 요청했습니다. 항소는 청문회가 끝날 때까지 거래 중단을 일시 중지합니다. 이는 2024년 5월 7일에 받은 이전의 결함 통지서에 따른 것으로, 이후 Evaxion은 2024년 11월 4일에 만료된 180일 연장을 받았습니다. 회사는 사업 개발 수익 및 자본 시장 활동을 통해 주주의 자본을 증가시킬 계획이지만, 준수를 보장할 수는 없습니다.
Evaxion Biotech (NASDAQ: EVAX) a reçu une décision de radiation de Nasdaq en raison de son incapacité à maintenir un capital d'actionnaires d'au moins 2,5 millions de dollars. L'entreprise a fait appel de cette décision et a demandé une audience, cherchant une prolongation de 180 jours supplémentaires pour se conformer aux exigences en matière de capital de Nasdaq. L'appel suspendra toute suspension de négociation jusqu'à la fin du processus d'audience. Cela fait suite à une lettre de carence reçue le 7 mai 2024, après laquelle Evaxion a obtenu une prolongation de 180 jours qui a expiré le 4 novembre 2024. L'entreprise prévoit d'augmenter le capital des actionnaires grâce à des revenus provenant du développement commercial et des activités sur les marchés de capitaux, bien que la conformité ne puisse être garantie.
Evaxion Biotech (NASDAQ: EVAX) hat eine delisting-Anordnung von Nasdaq erhalten, da es versäumt hat, ein Eigenkapital von mindestens 2,5 Millionen Dollar aufrechtzuerhalten. Das Unternehmen hat gegen die Entscheidung Berufung eingelegt und um eine Anhörung gebeten, um eine weitere 180-tägige Verlängerung zur Einhaltung der Eigenkapitalanforderungen von Nasdaq zu erhalten. Die Berufung wird jegliche Handelsaussetzung bis zum Abschluss des Anhörungsprozesses aussetzen. Dies folgt auf ein vorhergehendes Mängelschreiben vom 7. Mai 2024, nach dem Evaxion eine 180-tägige Verlängerung gewährt wurde, die am 4. November 2024 abgelaufen ist. Das Unternehmen plant, das Eigenkapital der Aktionäre durch Einkünfte aus Geschäftsentwicklung und Aktivitäten am Kapitalmarkt zu erhöhen, wobei jedoch die Einhaltung nicht garantiert werden kann.
- Trading suspension stayed during appeal process
- Company actively pursuing compliance through business development and capital markets activities
- Failed to maintain required $2.5M stockholders' equity
- Risk of potential Nasdaq delisting
- Previous 180-day compliance extension expired without meeting requirements
- Challenging market conditions affecting ability to raise equity
Insights
The delisting determination from Nasdaq represents a significant challenge for Evaxion Biotech, highlighting severe financial distress with stockholders' equity falling below the required
The failure to meet equity requirements after the initial extension period is particularly concerning given the company's micro-cap status (
- As anticipated, Evaxion has received a delisting determination
- The determination has been appealed by Evaxion requesting a hearing on the matter and seeking another 180-day extension to comply with Nasdaq’s equity requirement
- Evaxion remain committed to ensuring compliance and maintain our Nasdaq listing
COPENHAGEN, Denmark, November 13, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has, as anticipated, received a letter dated November 11, 2024, with a delisting determination from Nasdaq Stock Market LLC (“Nasdaq”) for failure to maintain stockholders’ equity of at least
Evaxion has already appealed the determination by requesting a hearing on the matter and will seek another 180-day extension to comply with Nasdaq’s equity requirement. The appeal will stay any trading suspension of our American Depositary Shares until completion of the Nasdaq hearing process and expiration of any additional extension period granted by the panel following the hearing. During any additional extension, Evaxion intends to regain compliance and maintain its Nasdaq listing, however no guarantee of such compliance can be given.
Following a deficiency letter from Nasdaq received on May 7, 2024, for failure to maintain stockholders’ equity of at least
As noted in our third quarter 2024 business update of October 31, 2024, we remain committed to ensuring compliance with the Nasdaq minimum stockholder’s equity requirement and to maintain our listing.
We will pursue an increase in stockholder’s equity via a combination of business development income and capital markets activities. However, the current equity market environment, the geopolitical uncertainties and timing of business development activities have impacted timing for the full required increase in stockholder’s equity.
We are in constructive dialogue with Nasdaq regarding the process for regaining compliance, though we cannot guarantee compliance or that an extension will be granted.
Contact information
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion-biotech.com
About EVAXION
Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from the worldwide ongoing COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia and the Middle East; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
Why is Evaxion Biotech (EVAX) facing Nasdaq delisting?
What actions is Evaxion (EVAX) taking to prevent delisting from Nasdaq?
When did Evaxion's (EVAX) initial compliance extension expire?